Vinorelbine in breast cancer

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 16, 2008, Pages 2901-2910

  Bonneterre, Jacques ^a,b   Penel, Nicolas ^a  

^a CENTRE OSCAR LAMBRET   (France)

^b UNIV LILLE   (France)

Author keywords

Adjuvant; Breast cancer; Metastatic; Polychemotherapy; Vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ABDOMINAL PAIN; ADJUVANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG HALF LIFE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; RECOMMENDED DRUG DOSE; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADJUVANTS, PHARMACEUTIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; HUMANS; NEOPLASM STAGING; VINBLASTINE;

EID: 56749138537     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.16.2901     Document Type: Article

References (81)

1. Bonnneterre J, Chevalier B, Focan C, et al. Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). Ann Oncol 2001;12:1683-91
2. Marty M, Fumoleau P, Adenis A, et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001;12(11):1643-49
3. Bourgeois H, Vermorken J, Dark G, et al. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. Cancer Chemother Pharmacol 2007;60:407-13
4. Gebbia V, Puozzo C. Oral versus intravenous vinorelbine: clinical safety profile. Expert Opin Drug Saf 2005;4(5):915-28
5. Nolé F, Catania C, Sanna G, et al. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 2006;17:322-9
6. Delcambre C, Veyret C, Levy C, et al. A phase I/II study of capecitabine (X) combined with oral vinorelbine (N) as first- or second-line chemotherapy in patients (pts) with locally advanced or metastatic breast cancer (MBC) [abstract 1081]. Breast Cancer Res Treat 2005;94(Suppl 1):S67
7. Kellokumpu-Lethtinen PL, Sunela KS, Lehtinen I, et al. A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer 2006;7(5):401-5
8. Delva R, Pienkowski T, Tubiana N, et al. Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study. Cancer Chemother Pharmacol 2007;59:703-9
9. Bonneterre J, Campone M, Koralewski P, et al. Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study. Cancer Chemother Pharmacol 2007;60:365-73
10. Degardin M, Bonneterre J, Hecquet B, et al. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994;5(5):423-6
11. Mano M. Vinorelbine in the management of breast cancer: new perspectives, revived role in the era of targeted therapy. Cancer Treat Rev 2006;32:106-18
12. Dieras V, Extra JM, Bellissant E, et al. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol 1996;14(12):3097-104
13. Nole F, de Braud F, Aapro M, et al. Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. Ann Oncol 1997;8(9):865-70
14. Berruti A, Sperone P, Bottini A, et al. Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. J Clin Oncol 2000;18(19):3370-7
15. Petit T, Benider A, Yovine A, et al. Phase II study of an oxaliplatin/ vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer. Anticancer Drugs 2006;17(3):337-43
16. Schmid P, Heilmann V, Schulz CO, et al. Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study. J Cancer Res Clin Oncol 2005;131:568-74
17. Blajman C, Balbiani L, Block J, et al. A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma. Cancer 1999;85(5):1091-7
18. Ejlertsen B, Mouridsen HT, Langkjer ST, et al. Scandinavian Breast Group Trial (SBG9403). Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol 2004;22(12):2313-20
19. Martin M, Ruiz A, Muñoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007;8:219-25
20. Bensalem A, Bouzid K. Gemcitabine/paclitaxel compared to gemcitabine/ vinorelbine in metastatic breast cancer: an interim analysis. ASCO 2007. J Clin Oncol 2007;25(18S):1097
21. Von Minckwitz G, Blohmer JU, Raab G, et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005;16(1):56-63
22. Harris LN, You F, Schnitt SJ, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007;13(4):1198-207
23. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20
24. Kerbrat P, Roché H, Bonneterre J, et al. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial. Br J Cancer 2007 Jun 4;96(11):1633-8
25. Verma S, Clemons M, Dranitsaris G, et al. Survival differences observed in anthracycline and taxane refractory metastatic breast cancer patients treated with capecitabine when compared with vinorelbine [abstract 5050]. In: Program and Abstracts of the 27th San Antonio Breast Cancer Symposium; 2004 December 8-11; San Antonio, TX
26. Le Lay K, Myon E, Hill S, et al. Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system. Eur J Health Econ 2007;8:145-51
27. Catania C, Didier F, Leon ME, et al. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Res Treat 2005;92:265-72
28. Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11(7):1245-52
29. Garcia-Conde J, Lluch A, Martin M, et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994;5(9):854-7
30. Romero A, Rabinovich MG, Vallejo CT, et al. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994;12(2):336-41
31. Weber BL, Vogel C, Jones S, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995;13(11):2722-30
32. Bruno S, Puerto VL, Mickiewicz E, et al. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol 1995;18(5):392-6
33. Vogel C, O'Rourke M, Winer E, et al. Vinorelbine as firstline chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999;10(4):397-402
34. Terenziani M, Demicheli R, Brambilla C, et al. Vinorelbine: an active, non-cross-resistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat 1996;39(3):285-91
35. Twelves CJ, Dobbs NA, Curnow A, et al. A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 1994;70(5):990-3
36. Rossi A, Gridelli C, Gebbia V, et al. Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer. Anticancer Res 2003;23(2C):1657-64
37. Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001;92(9):2267-72
38. Udom DI, Vigushin DM, Linardou H, et al. Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. Eur J Cancer 2000;36(2):177-82
39. Barni S, Ardizzoia A, Bernardo G, et al. Vinorelbine as single agent in pretreated patients with advanced breast cancer. Tumori 1994;80(4):280-2
40. Gasparini G, Caffo O, Barni S, et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 1994;12(10):2094-101
41. Fazeny B, Zifko U, Meryn S, et al. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - a phase II study. Cancer Chemother Pharmacol 1996;39(1-2):150-6
42. Nistico C, Garufi C, Milella M, et al. Weekly schedule of vinorelbine in pretreated breast cancer patients. Breast Cancer Res Treat 2000;59(3):223-9
43. Papaldo P, Fabi A, Ferretti G, et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol 2006;17:630-6
44. Chan A, Martin M, Untch M, et al. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer 2006;95:788-93
45. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21(15):2889-95
46. Bernardo G, Palumbo R, Bernardo A, et al. Final results of phase II study of weekly trastuzumab and vinorelbine in chemonaive patients with HER2-overexpressing metastatic breast cancer [abstract 731]. Proc Am Soc Clin Oncol 2004;23:59
47. Burstein HJ, Keshaviah A, Baron A, et al. Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: the TRAVIOTA study [abstract 650]. J Clin Oncol 2006;24:40s
48. Chan A, Petruzelka L, Untch M, et al. Long term survival of vinorelbine (N) and trastuzumab (H) as first line therapy for HER2-positive metastatic breast cancer patients (HER2-MBC) (pts) [abstract 587]. Proc Am Soc Clin Oncol 2005;23
49. + metastatic breast cancer. Oncologist 2002;7:410-7
50. Bayo-Calero JL, Mayordomo-Camara JI, Sanchez-Rovira P, et al. A multicenter study with trastuzumab and vinorelbine as first and 2nd line treatment in patients (pats) with Her2 positive Metastatic Breast Cancer (MBC) [abstract 5069]. In: Program and Abstracts of the 27th San Antonio Breast Cancer Symposium; 2004 December 8-11; San Antonio, TX
51. Franquesa R, Centelles M, Villadiego K, et al. A multicenter study of trastuzumab (H) and vinorelbine (N) as first and second line therapy for patients (pts) with HER2-positive metastatic breast cancer (HER2+MBC) [abstract 868]. Proc Am Soc Clin Oncol 2005;23(16):63S
52. De Maio E, Pacilio C, Gravina A, et al. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial. BMC Cancer 2007;7:50
53. Bartsch R, Wenzel C, Altorjai G, et al. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. Breast Cancer Res Treat 2007;102(3):375-81
54. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-30
55. Lal A, Alidina A. Interim analysis of a phase II study of biochemotherapy in metastatic breast cancer (MBC) [abstract 470]. Eur J Cancer 2005;3(Suppl):131
56. Porta VG, Martin M, Gil M, et al. Evaluation of vinorelbine (N) and trastuzumab (H) as first-line therapy for patients (pts) with HER2-positive metastatic breast cancer (HER2-MBC): impact on clinical response and cardiac function. ASCO Annual Meeting Proceedings (post-meeting edition). J Clin Oncol 2004;22(14S):636
57. De Wit M, Harbeck N, Thomssen C, et al. Interim results of a prospective, open-label, multicentre Phase II trial of the efficacy and safety of vinorelbine (N) and trastuzumab (H) in patients with HER2-positive metastatic breast cancer (MBC). ASCO Annual Meeting Proceedings (post-meeting edition). J Clin Oncol 2004;22(14S):831
58. Chan A. A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. Ann Oncol 2007;18:1152-8
59. Romero Acuna L, Langhi M, Perez J, et al. Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 1999;17(1):74-81
60. Blasinska-Moriawiec M, Ulanska M, Zambrano Quispe O, et al. Phase II study of vinorelbine (VRL) alternating i.v. and oral in combination with docetaxel (DTX) as 1st line chemotherapy (CT) of metastatic breast cancer (MBC) [abstract 783]. J Clin Oncol 2005;23(16S)
61. Kornek GV, Ulrich-Pur H, Penz M, et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 2001;19(3):621-7
62. Brugnatelli S, Riccardi A, Danova M, et al. Sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracylines: a phase II study. Oncol Rep 2001;8:801-5
63. Ghosn M, Chahine G, Kattan J, et al. Vinorelbine (N)-capecitabine (C) combination in advanced breast cancer (ABC): long-term results of two multicentric phase II trials. Proc Am Soc Clin Oncol 2005;23(16S, Part I of II): abstr. 673
64. Tubiana-Mathieu N, Bougnoux P, Becquart D, et al. An international phase II study of an all-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (BMC). ASCO 2007. J Clin Oncol 2007;25(18S):1056
65. Nolé F, Catania C, Sanna G, et al. Phase II study of an all-oral regimen combining oral vinorelbine with capecitabine as first-line chemotherapy (CT) of metastatic breast cancer [abstract 2114]. Eur J Cancer 2007;5(4):218
66. Ahn JH, Kim SB, Kim SM, et al. Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci 2004;19:547-53
67. Schmid P, Heilman V, Schulz C-O, et al. Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study. J Cancer Res Clin Oncol 2005;131:568-74
68. Gennatas C, Michalaki V, Mouratidou D, et al. Gemcitabine in combination with vinorelbine for heavily pretreated advanced breast cancer. Anticancer Res 2006;26:549-52
69. Botto HG, Botto ME. Gemcitabine and vinorelbine as third-line therapy in elderly patients (pts) with advanced breast cancer (ABC) pretreated with taxanes and anthracyclines. ASCO 2007. J Clin Oncol 2007;25(18S):1110
70. Spielmann M, Dorval T, Turpin F, et al. Phase II trial of vinorelbine/ doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 1994;12(9):1764-70
71. Nistico C, Garufi C, Barni S, et al. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. Ann Oncol 1999;10:937-42
72. Vici P, Colucci G, Gebbia V, et al. First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. J Clin Oncol 2002;20(11):2689-94
73. Serin D, Verrilli M, Jones A, et al. Vinorelbine alternating oral and intravenous plus epirubicin in first-line of metastatic breast cancer: results of a mulicentre phase II study. Br J Cancer 2005;92:1989-96
74. Ardavanis A, Mavroudis D, Kalbakis K, et al. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study. Cancer Chemother Pharmacol 2006;58(6):742-8
75. Namer M, Soler-Michel P, Turpin F, et al. Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer. Eur J Cancer 2001;37(9):1132-40
76. Van Praagh I, Cure H, Leduc B, et al. Efficacy of primary chemotherapy regimen combining vinorelbine, epirubicin and methotrexate (VEM) as neo-adjuvant treatment in 89 patients with operable breast cancer. Oncologist 2002;7(5):418-23
77. Braud AC, Levy E, Feuilhade F, et al. Combination of vinorelbine, epirubicin, and cyclophosphamide as neoadjuvant chemotherapy for locally advanced breast cancer. Phase II study. Am J Clin Oncol 2002;25(3):303-7
78. Livi L, Paiar F, Santini R, et al. Alternating intravenous and oral vinorelbine plus epirubicin with pegfilgrastim as neoadjuvant treatment of locally advanced breast cancer. Anticancer Drugs 2006;17(9):1081-5
79. Chua S, Smith IE, A'Hern RP, et al. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol 2005;16(9):1435-41
80. Moliterni A, Bolognesi A, Mansutti M, et al. Feasibility and locoregional activity of primary chemotherapy (PC) with doxorubicin/ paclitaxel (AT) versus epirubicin/vinorelbine (EV) in operable breast cancer. A study by the Michelangelo Foundation [abstract 2087]. In: Program and Abstracts of the 27th San Antonio Breast Cancer Symposium; 2004 December 8-11; San Antonio, TX
81. Limentani SA, Brufsky AM, Erban JK, et al. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 2007;25(10):1232-8